National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand: position statement on lipid management--2005.

Andrew Tonkin; Philip Barter; James Best; Andrew Boyden; John Furler; Ken Hossack; David Sullivan; Peter Thompson; Margarite Vale; Catherine Cooper; Malia Robinson; Eleanor Clune

doi:10.1016/j.hlc.2005.10.010

National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand: position statement on lipid management--2005.

Andrew Tonkin, Philip Barter, James Best, Andrew Boyden, John Furler, Ken Hossack, David Sullivan, Peter Thompson, Margarite Vale, Catherine Cooper, Malia Robinson, Eleanor Clune

Chronic Disease & Ageing

Research output: Contribution to journal › Comment / Debate › Other › peer-review

125 Citations (Scopus)

Original language	English
Pages (from-to)	275-291
Number of pages	17
Journal	Heart Lung and Circulation
Volume	14
Issue number	4
DOIs	https://doi.org/10.1016/j.hlc.2005.10.010
Publication status	Published - Dec 2005

Access to Document

10.1016/j.hlc.2005.10.010

Cite this

Tonkin, A., Barter, P., Best, J., Boyden, A., Furler, J., Hossack, K., Sullivan, D., Thompson, P., Vale, M., Cooper, C., Robinson, M., & Clune, E. (2005). National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand: position statement on lipid management--2005. Heart Lung and Circulation, 14(4), 275-291. https://doi.org/10.1016/j.hlc.2005.10.010

@article{b29ac3745a7a45988f375c5aa3b9be0f,

title = "National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand: position statement on lipid management--2005.",

author = "Andrew Tonkin and Philip Barter and James Best and Andrew Boyden and John Furler and Ken Hossack and David Sullivan and Peter Thompson and Margarite Vale and Catherine Cooper and Malia Robinson and Eleanor Clune",

note = "Funding Information: David Sullivan has been involved in research initiated by Pfizer, AstraZeneca and Merck Sharpe & Dohme and research funded by Aventis. He has acted in an advisory capacity or received travel assistance or fees for service from AstraZeneca, Merck Sharpe & Dohme, Pfizer and Novartis. Funding Information: Andrew Tonkin has received research funding from AstraZeneca, Bristol-Myers Squibb and Fournier, been involved in research initiated by Merck Sharpe & Dohme, and acted in an advisory capacity or received travel assistance or fees for service from AstraZeneca, Bristol-Myers Squibb, Pfizer, Sankyo, Fournier and Servier. Funding Information: James Best has been involved in research funded by Eli Lilly, Laboratoires Fournier and Pfizer, and acted in an advisory capacity or received travel assistance or fees for service from AstraZeneca, Pfizer, Merck Sharpe & Dohme, Aventis, Eli Lilly and Laboratoires Fournier. ",

year = "2005",

month = dec,

doi = "10.1016/j.hlc.2005.10.010",

language = "English",

volume = "14",

pages = "275--291",

journal = "Heart Lung and Circulation",

issn = "1443-9506",

publisher = "Elsevier",

number = "4",

}

Tonkin, A, Barter, P, Best, J, Boyden, A, Furler, J, Hossack, K, Sullivan, D, Thompson, P, Vale, M, Cooper, C, Robinson, M & Clune, E 2005, 'National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand: position statement on lipid management--2005.', Heart Lung and Circulation, vol. 14, no. 4, pp. 275-291. https://doi.org/10.1016/j.hlc.2005.10.010

TY - JOUR

T1 - National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand

T2 - position statement on lipid management--2005.

AU - Tonkin, Andrew

AU - Barter, Philip

AU - Best, James

AU - Boyden, Andrew

AU - Furler, John

AU - Hossack, Ken

AU - Sullivan, David

AU - Thompson, Peter

AU - Vale, Margarite

AU - Cooper, Catherine

AU - Robinson, Malia

AU - Clune, Eleanor

N1 - Funding Information: David Sullivan has been involved in research initiated by Pfizer, AstraZeneca and Merck Sharpe & Dohme and research funded by Aventis. He has acted in an advisory capacity or received travel assistance or fees for service from AstraZeneca, Merck Sharpe & Dohme, Pfizer and Novartis. Funding Information: Andrew Tonkin has received research funding from AstraZeneca, Bristol-Myers Squibb and Fournier, been involved in research initiated by Merck Sharpe & Dohme, and acted in an advisory capacity or received travel assistance or fees for service from AstraZeneca, Bristol-Myers Squibb, Pfizer, Sankyo, Fournier and Servier. Funding Information: James Best has been involved in research funded by Eli Lilly, Laboratoires Fournier and Pfizer, and acted in an advisory capacity or received travel assistance or fees for service from AstraZeneca, Pfizer, Merck Sharpe & Dohme, Aventis, Eli Lilly and Laboratoires Fournier.

PY - 2005/12

Y1 - 2005/12

UR - http://www.scopus.com/inward/record.url?scp=32644479927&partnerID=8YFLogxK

U2 - 10.1016/j.hlc.2005.10.010

DO - 10.1016/j.hlc.2005.10.010

M3 - Comment / Debate

C2 - 16361000

AN - SCOPUS:32644479927

SN - 1443-9506

VL - 14

SP - 275

EP - 291

JO - Heart Lung and Circulation

JF - Heart Lung and Circulation

IS - 4

ER -

National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand: position statement on lipid management--2005.

Access to Document

Other files and links

Cite this